In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
During the COVID-19 pandemic he was part of the “public face” for media and community groups, conducting over 100 interviews, seminars and media conferences, including with the Prime Minister and Health Minister.
He became synonymous with, and the public face of, the Therapeutic Goods Administration, leaving behind an extraordinary record of public service.
During this time it was his reassurances that left Australians confident in the approval and regulation of medicines, vaccines and treatments.
“Professor Skerritt has had many achievements over the course of his career including Implementing the Medicines and Medical Devices Review, digital transformation, the regulation of medicinal cannabis, the rapid registration of COVID vaccines and treatments and playing a leading role in international harmonisation of regulation.”, said The Hon Mark Butler MP, Minister for Health and Aged Care in a press release issued in February the same year.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
About ARCS and its transformation in 2023
ARCS Australia is the association for people working on the development of therapeutics. The ARCS conference brings over 1500 people across the sector, in Australia, with international speakers coming this year. The conference runs over 3 days with 7 concurrent streams that cover all the areas that are involved in the development of therapeutics, including clinical research, regulatory affairs and pharmacovigilance.
The focus for ARCS at this year’s conference has been building competency frameworks in the areas that members work. As a significant step, ARCS is transforming into a professional body that both recognises and develops people into specific competencies that are required for the roles that those people are undertaking.
Dr Shanny Dyer states, “One of the key goals that ARCS is undertaking over this strategic period is to implement the professionalisation of our sector. Whilst we’ve been very clearly developing products that have safety, quality and efficacy, we now need to work on the quality of our staff, their ability to develop products and have a safe pair of hands and to work efficiently as well.”
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
-
Analogy of the system, rather than the ED front door
“The problem of blockages shows up in ambulance ramping and long wait times, but this is a complex issue requiring whole-of-health system solutions,” according to Professor Hugh Grantham, Chair of Emergency Medicine Foundation in an interview with Australian Health Journal.
-
Being Part of the New Health Frontier
In November last year, the House of Representatives Standing Committee on Health, Aged Care and Sport delivered its bipartisan report “The New Frontier: Delivering better health for all Australians” on the approval processes for new drugs and novel medical technologies in Australia.
Australian Health Journal spoke to some of the industry bodies who were part of the Inquiry, for their comments on the process, the report and hopes in the recommendations being implemented.
